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Percutaneous coronary intervention (PCI) has evolved greatly in the last 40 years since its introduction by 
Andreas Grüntzig in 1977. Since then, we’ve observed an evolution in balloons, the development of stents, 
changes in stent structure, development of drug eluting stents, improvements in strut design, thickness and 
even their polymeric coating. Most recently we saw the rise and “fall” of bioabsorbable scaffolds for PCI. 
Trials with the most diverse devices for PCI and diagnostic techniques have been conducted. Two of the 
most recent trials were reported in the last year and deserve special attention—SYNTAX II and SYNTAX 
III. These trials are completely different in design but present valuable information for doctors managing 
coronary artery disease (CAD). Both trials take into account contemporary technology for assessing and 
treating CAD. The first uses so-called “state-of-the-art” PCI and compares the outcomes of that approach 
with the outcomes of the PCI arm of the pivotal SYNTAX trial. SYNTAX III Revolution on the other hand 
does not focus on clinical endpoints: it is a blinded trial that does not randomize patients but randomizes 
doctors (“the heart team”) to make a decision on the best treatment for complex CAD. This decision was 
based either on multi-slice CT with physiological assessment using FFRCT or on conventional angiography. 
In this review we bring the most important aspects of those trials and the key messages for surgeons together; 
also, what the surgeon may expect in the future after the publication of these interesting concepts.
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Introduction
Over the past 40 years of percutaneous coronary intervention 
(PCI), the evolution in techniques and devices has been (and 
still is) tremendous. Still, the debate over the best approach 
for treating complex coronary artery disease (CAD) persists. 
In the last decade the SYNTAX trial showed superiority 
of surgery over percutaneous treatment using the first-
generation drug-eluting stent (Taxus®) in three-vessel 
disease patients (3VD) (1,2). For diabetic 3VD patients, this 
superiority was confirmed in the FREEDOM trial (3). With 
the use of new-generation drug-eluting stents, the BEST 
trial also demonstrated that PCI did not outrank CABG as 
the superior treatment for these subjects (4).
Regardless of the ongoing PCI vs. CABG comparisons, 
the field of percutaneous intervention has evolved, with 
development of new devices, technology and techniques. 
From balloon angioplasty, to implantation of stents, to the 
development of drug-eluting stents, to the redesign of shape 
and thickness of their struts, to bioabsorbable scaffolds, 
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the field has continued to evolve since Andreas Grüntzig’s 
work in 1977. This evolution has not been limited to device 
improvement, but has also involved adjunctive therapy, image 
guidance and physiological assessment of coronary stenosis.
The recent SYNTAX II trial (5) is a new milestone in 
the approach to 3VD. This trial does not have the purpose 
of posing PCI against CABG, rather, it compares all the 
currently available techniques for the so-called “state-of-
the-art” PCI and analyses the improvement of PCI over 
time. This is done by comparing with the outdated PCI arm 
of the SYNTAX I trial (2).
Among diagnostic tools, the improvement in non-invasive 
imaging has enabled coronary computed tomography 
angiography (CCTA) to reach a high standard level of 
accuracy in assessing the anatomy of the diseased coronary 
artery (6) and its physiological significance via FFRCT (7). 
The hypothesis of the SYNTAX III Revolution trial is that 
a heart-team decision for the best CAD treatment (CABG 
or PCI) would be the same, whether assessing the coronary 
artery tree with new CCTA diagnostic tools or using 
conventional invasive angiography (8).
Although these two trials are completely different in 
concept and design, they gather information of utmost 
importance and interest for physicians who deal directly 
with CAD patients, especially cardiac surgeons performing 
coronary artery bypass graft (CABG). We aimed to review 
the main findings of these ground-breaking studies and to 
provide the surgical community with concise information 
stemming from these two trials. 
SYNTAX II trial
Design and patient selection
The SYNTAX II trial is a multicenter, all-comers, open-
label, single-arm trial that screened patients with de novo 3VD 
who were candidates for revascularization (9) (Video 1). 
It was designed to challenge the current guidelines’ 
recommendation of only percutaneously treating patients 
with 3VD and an anatomical SYNTAX score of 22 or 
less. The moral justification to do so relies on the use of 
the SYNTAX score II. This score modulates the impact 
of the anatomical SYNTAX score in decision making 
according to the interaction of the clinical characteristics 
and comorbidities with purely anatomical equipoise (score 
of 15) that has been established after the SYNTAX I trial (9). 
Recruitment occurred form February 2014 until 
November 2015 and included 454 patients. Patients were 
selected after screening from the local heart team (comprised 
of interventional cardiologists and cardiac surgeons) based 
on the recommendation of the SYNTAX score II, which 
had to demonstrate equipoise between PCI and CABG (i.e., 
both strategies were recommended based on the predicted 
4-year mortality) (10). Patients were referred for PCI with 
a state-of-the-art approach, i.e., the revascularization was 
physiology guided, with the assistance of imaging guidance, 
use of novel stents and specialized personnel to treat CTO 
and bifurcation lesions.
The SYNTAX score II
The SYNTAX score II is a clinical tool that combines 
clinical variables with the anatomical SYNTAX score, 
providing expected 4-year mortality for both CABG and 
PCI—thus recommending either PCI only, CABG only or 
equipoise in treatment based on long-term mortality.
SYNTAX score II is based on interaction between 
clinical variables and the anatomical SYNTAX score using 
Cox model as the regression model, weighing the balance 
of PCI vs. CABG towards one or the other (Figure 1). The 
clinical variables included in the SYNTAX score II are age, 
renal function (creatinine clearance), left ventricle ejection 
fraction, left main involvement, sex, presence of chronic 
obstructive pulmonary disease and of peripheral vascular 
disease. The score is easily assessable via a web calculator 
(www.syntaxscore.com) (11) and follows the below 
nomogram for bedside application (Figure 2).
State-of-the-art PCI
Another interesting and innovative aspect of this trial is the 
so-called state-of-the-art approach for PCI. This approach 
combines physiologically guided intervention, the use of 
a novel thin strut (70 µm, with abluminal biodegradable 
polymer coating stent—SYNERGY, Boston Scientific) and 
a mandatory post-PCI intravascular ultrasound (IVUS) 
assessment of adequate stent expansion and apposition (12).
Additionally, the treatment of bifurcation lesions 
was made according to the recommendation of the 
European Bifurcation Club’s consensus (13) and chronic 
total occlusion (CTO) revascularization was preferably 
performed by a dedicated CTO operator.
Physiology guided revascularization
Physiology guided PCI consists of evaluating the functional 
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Figure 1 Demonstration of the concept of interaction—interaction between the mode of revascularization, anatomical SYNTAX score and 
the clinical characteristics and comorbidities. (A) Effects of the different variables are represented visually as a log hazard ratio for CABG 
(straight line) and PCI (dotted line) on the y-axis for each predictor. Each graph represents one predictor. Note the differing gradients of the 
hazards for PCI and CABG, leading to the hazards crossing at an anatomical SYNTAX score of 15. At this cross-over point of hazards, the 
mortality risk is much the same between CABG and PCI. This threshold of cross-over of hazards will vary according to the variables—being 
lower for female sex, reduced LVEF, and younger age, and higher for COPD, left main disease, and older age. Peripheral vascular disease 
(P=1.00) equally affected mortality following each mode of revascularization (somewhat parallel lines). (B) the graphic representation using 
a weight scale balance—the weight represents the favorable effect (e.g., left main stem favors PCI). Reproduced and modified from Farooq 
et al. (10). CABG, coronary artery bypass surgery; PCI, percutaneous coronary intervention; HR, hazard ratio; CrCl, creatinine clearance; 
LVEF, left ventricular ejection fraction; left main, unprotected left main coronary artery disease; 3VD, three-vessel disease; LMS, left main 
stem; COPD, chronic obstructive pulmonary disease; PVD, peripheral vascular disease.
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severity of a stenosis in the coronary artery to determine 
the need for revascularization. Currently it is performed 
using fractional flow reserve (FFR) or instantaneous 
wave-free ratio (iFR). FFR is assessed during maximal 
reactive hyperemia induced by intracoronary injection or 
intravenous infusion of adenosine (an off-label use of that 
compound). The administration of adenosine commonly 
causes the patient discomfort. The iFR is the instantaneous 
diastolic pressure gradient between the aorta and the 
pressure distal to the stenosis and does not necessitate the 
use of induced hyperemia. At the time of the design of the 
SYNTAX II trial, the equivalence of iFR and FFR was not 
yet established and was a topic of intense debate. Therefore, 
outside of a clear threshold for revascularization or deferral, 
there was a gray zone in measurement of iFR where it was 
recommended to perform an FFR with reactive hyperemia 
(Figure 3). The importance of this technology for functional 
assessment of a coronary lesion has been demonstrated 
in the large clinical trials FAME (14) and FAME 2 (15). 
In the FAME trial (including over one thousand patients) 
Figure 2 SYNTAX score II nomogram for offline application. With this nomogram the sum of points using the 8 factors (SYNTAX score, 
age, CrCl, LVEF, left main, sex, COPD and PVD) can be used to assess the expected 4-year mortality for the individual patient either for 
CABG or PCI. For example, a 60-year-old man with an anatomical SYNTAX score of 30, unprotected left main coronary artery disease, 
creatinine clearance of 60 mL/min, an LVEF of 50%, and COPD, would have 41 points (predicted 4-year mortality 16.3%) to undergo 
CABG and 33 points (predicted 4-year mortality 8.7%) to undergo PCI respectively. The same example without COPD included would 
lead to identical points (29 points) and 4-year mortality predictions (6.3%) for CABG and PCI. Because of the rarity of complex coronary 
artery disease in premenopausal women, mortality predictions in younger women are predominantly based on the linear relation of age with 
mortality. The differences in mortality predictions in younger women between CABG and PCI will therefore be affected by larger 95% CI 
than those in older women. Reproduced and modified from Farooq et al. (10). CABG, coronary artery bypass surgery; PCI, percutaneous 
coronary intervention; CrCl, creatinine clearance; LVEF, left ventricular ejection fraction; left main, unprotected left main coronary artery 
disease; 3VD, three-vessel disease; COPD, chronic obstructive pulmonary disease; PVD, peripheral vascular disease.
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Figure 3 Flowchart of the SYNTAX II study for the physiological assessment. Instantaneous wave-free ratio (iFR) was performed in 
all lesions intended to be treated. If the assessment resulted in a ratio of less than 0.86 or more than 0.93, no further action in regard to 
physiological assessment was necessary. For results within the grey zone (between 0.86 and 0.93), fractional flow reserve (FFR) assessment 
was required. iFR assesses the ratio between the pressures in the distal coronary and aorta (Pd/Pa) at a specific time frame called the wave-
free period (in diastole), without the need for induced hyperemia (upper corners—right and left). FFR assesses the mean pressures (red lines) 
of the Pd/Pa after the induced hyperemia with adenosine (center of the image).
the investigators demonstrated that compared with 
angiography-guided PCI, physiology-guided PCI (with 
FFR) was associated with lower rates of the composite 
endpoint of death, non-fatal myocardial infarction (MI), and 
repeat revascularization at 1 year, and also associated with 
fewer stents used per patient (physiology guided 1.9±1.3 
stents vs. angiography guided 2.7±1.2 stents, P<0.001) in 
multivessel diseased patients. 
A recent systematic review comprising 51,350 patients 
from 11 studies comparing physiology-guided versus 
angiography-guided PCI showed that the first is associated 
with lower likelihood of MI during hospitalization (OR 
0.54, 95% CI: 0.39–0.75, P<0.001) and at follow-up (OR 
0.53, 95% CI: 0.40–0.70, P<0.001), lower in-hospital (OR 
0.51, 95% CI: 0.37–0.70, P<0.001), and follow-up (OR 0.63, 
95% CI: 0.47–0.86, P=0.004) major adverse cardiovascular 
events. Physiology-guided PCI also resulted in lower 
procedure cost (16). 
Physiology guidance has proven to lower cardiovascular 
event rates not only for percutaneous revascularization but 
also for CABG. A recent 6-year follow-up study of 627 
consecutive patients has shown that physiology-guided 
surgical revascularization is associated with a lower rate of 
all cause death or MI [16% vs. 25%; hazard ratio 0.59 (95% 
CI: 0.38–0.93), P=0.020] as compared with the conventional 
angiography-guided CABG (17). The iFR technique has 
the advantage of precluding the use of adenosine to achieve 
maximum hyperemia. iFR has been shown to be non-
inferior to FFR in two major clinical outcome trials—the 
DEFINE-FLAIR and the SWEEDHEART (18,19).
Main findings
The SYNTAX II trial compared state-of-the-art PCI 
patients with a historical cohort of PCI patients from the 
SYNTAX I trial who had a matched “equipoise” predicted 
mortality at 4 years (5). Identical definitions of outcomes 
used in SYNTAX I were applied in the SYNTAX II 
trial. The primary outcome of the study was a composite 
endpoint of major adverse (patient-oriented) cardiac 
Patient included in the SYNTAX II study
iFR < 0.86 iFR 0.86–0.93
Optimal medical therapy with strict LDL control (≤1.8 mmol/L)
Without hyperemia 
iFR
iFR in all intended to treat stenoses
FFR
FFR
Hyperemia
Stenosis treated with 
SYNERGYTM EES 
Stenosis not treated
IVUS optimization 
iFR > 0.93
FFR > 0.80FFR ≤ 0.80
Without hyperemia 
iFR
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and cerebrovascular events (MACCE or PoCE—patient 
oriented composite endpoint) at 1-year follow-up. Major 
adverse cardiac and cerebrovascular event was defined as all-
cause death, stroke, any MI or any revascularization. Also, 
there was an exploratory short-term and 5-year follow-up 
comparison of the SYNTAX II patients with the equipoise-
derived patients in the CABG arm of the SYNTAX I trial. 
An independent clinical event committee adjudicated all 
events.
The baseline characteristics of the patients in both 
groups are shown in Table 1. Although the anatomical 
SYNTAX score is different between the groups, the 
SYNTAX score II (4-year predicted mortality) was similar 
between PCI groups. Patients undergoing state-of-the-art 
PCI experienced less PoCE (10.6% vs. 17.4%; HR 0.58, 
95% CI: 0.39–0.85, P=0.006) compared with the equipoise 
PCI arm of SYNTAX I. The difference was mainly driven 
by a significant reduction in the incidence of MI (HR 0.27, 
Table 1 Baseline clinical characteristic—SYNTAX II trial
Characteristics SYNTAX II (n=454) SYNTAX I PCI arm (n=315) P value
Age (years) 66.7±9.7 [454] 66.7±9.1 [315] 0.99
Male 93.2% (423/454) 93.0% (293/315) 0.93
Body mass index (kg/m
2
) 28.9±4.7 [449] 28.2±4.4 [315] 0.032
Diabetes mellitus type I or II 30.3% (135/446) 29.2% (92/315) 0.75
Insulin treated 8.5% (38/446) 10.5% (33/315) 0.36
Oral medication 19.5% (87/446) 16.8% (53/315) 0.35
Diet only 2.0% (9/446) 1.9% (6/315) 0.91
Current smoker 14.7% (64/435) 17.8% (56/315) 0.26
Previous myocardial infarction 12.5% (56/447) 28.7% (89/310) <0.001
Previous stroke 5.6% (25/449) 1.9% (6/315) 0.01
Hypertension 77.0% (344/447) 73.4% (229/312) 0.26
Hyperlipidemia 77.3% (341/441) 74.4% (232/312) 0.35
Creatinine clearance (mL/min) 82.0±26.9 [454] 87.3±28.5 [315] 0.008
Ejection fraction (%) 58.1±8.3 [454] 61.8±11.3 [315] <0.001
Peripheral vascular disease 7.7% (35/454) 9.5% (30/315) 0.37
COPD 10.8% (49/454) 12.7% (40/315) 0.42
Clinical presentation <0.001
Silent ischemia 6.7% (30/449) 13.3% (42/315)
Stable angina 68.8% (309/449) 61.6% (194/315)
Unstable angina 25.6% (115/449) 25.1% (79/315)
Anatomic SYNTAX score 20.3±6.4 [454] 22.8±8.7 [315] <0.001
SYNTAX score II PCI 30.2±8.6 [454] 30.6±8.7 [315] 0.528
Predicted 4-year mortality PCI (%) 8.9±8.8 [454] 9.2±8.7 [315] 0.64
SYNTAX score II CABG 29.1±10.4 [454] 29.1±9.6 [315] 1
Predicted 4-year mortality CABG (%) 9.0±9.3 [454] 8.5±8.1 [315] 0.44
PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease (Escaned 
et al. SYNTAX II).
476 Modolo et al. SYNTAX II and SYNTAX III for surgeons
© Annals of Cardiothoracic Surgery. All rights reserved. Ann Cardiothorac Surg 2018;7(4):470-482www.annalscts.com
95% CI: 0.11–0.70, P=0.007) and revascularization (HR 0.5 
7, 95% CI: 0.37–0.90, P=0.015). Rates of all-cause death 
(HR 0.69, 95% CI: 0.27–1.73, P=0.43) and stroke (HR 
0.69, 95% CI: 0.10–4.89, P=0.71) were similar (Figure 4). 
Another finding worthy of mentioning was the rate of 
stent thrombosis, which was lower with the SYNTAX II 
approach (HR 0.26, 95% CI: 0.07–0.97, P=0.045). The 
results were confirmed by sensitivity analyses of the primary 
endpoint adjusted by confounding factors using the inverse 
probability of treatment weighting (IPTW) approach and 
multivariate Cox regression analysis. The confounding 
factors used on the IPTW approach were: gender, age, 
diabetes status, hyperlipidemia, previous MI, left ventricular 
ejection fraction, creatinine clearance, number and length 
of the stents implanted and anatomical SYNTAX score.
The exploratory analysis comparing SYNTAX II 
PCI patients with the equipoise SYNTAX I CABG arm 
(simulating a state-of-the-art PCI vs. CABG for multivessel 
disease patients) showed no difference between the 
groups with regards to PoCE [10.6% vs. 11.2%; HR 0.91 
(95% CI: 0.59–1.14), P=0.684, respectively]. However, 
this comparison is merely exploratory; it compares 
contemporary state-of-the-art PCI patients with the 
historical (outdated) CABG cohort of the SYNTAX I trial. 
Thus, improvements in CABG techniques are not taken 
into account. Data not yet published comparing CABG 
patients from the EXCEL trial (20) with those from the 
SYNTAX I trial shows that the surgery has improved since 
SYNTAX. 
Most recently, the eagerly awaited results of the 2-year 
follow-up of the SYNTAX II trial were presented at the 
EuroPCR 2018 Congress in Paris—these results are yet to 
be published. At this mid-term follow-up, the main results 
held, i.e., the SYNTAX II strategy was associated with 
improved clinical outcomes at two years, compared with 
the matched patients treated percutaneously in the original 
SYNTAX I trial. Also, the 2-year exploratory comparison 
between SYNTAX II and matched CABG patients from the 
“historical” SYNTAX I trial suggests equivalent outcomes 
for PCI with CABG when the SYNTAX II strategy is 
followed (Figure 5).
Implication of the SYNTAX II trial for surgeons
In the field of coronary revascularization, multiple studies 
compare CABG with PCI in order to find the best 
option for patients with CAD. SYNTAX II is not such 
a trial. However, it brings some important key messages 
for interventional cardiologists and also for the surgical 
community.
An important message is that we are making progress 
with the “holistic” approach for treating CAD with PCI—
however, we cannot attribute improvement in outcomes 
to any specific change in our percutaneous approach. The 
introduction of physiology-guided therapy suggests that 
revascularization based on physiology has a cardioprotective 
effect that could become relevant for surgeons performing 
revascularization [suggested by Fournier et al. (17) in 
CABG patients]. This is especially important in a medical 
world where new potent pharmacological agents targeting 
coronary artery plaque regression are constantly being 
introduced and improved.
The importance of the SYNTAX score II as a tool for 
heart team decision making must be mentioned, since this 
score represents an integrated approach in selecting patients 
for surgery or PCI.
SYNTAX III Revolution trial
Heart team assessment
Currently, the treatment of choice for patients with complex 
multivessel CAD is CABG (2-4,21). A heart team approach 
(i.e., a team comprised of cardiac surgeon, interventional 
cardiologist and clinical cardiologist) is recommended by 
international guidelines for deciding the between CABG 
and PCI for 3VD patients (1,22). This decision is based 
mainly on the complexity of the CAD assessed by the 
anatomical SYNTAX score compounded with the patient’s 
comorbidities and clinical characteristics (23).
Until now, conventional coronary angiography was 
used for assessing CAD and for decision-making by the 
heart team. However, CCTA has arisen as a non-invasive 
tool capable of providing precise information on coronary 
stenosis and plaques (24-26). Furthermore, the physiological 
assessment of FFR non-invasively, with the use of the FFRCT 
has already been demonstrated to be accurate in patients 
with multivessel disease (27). Those were the basic concepts 
for the design of the SYNTAX III Revolution trial (Video 2).
The trial
The SYNTAX III Revolution trial tested the hypothesis 
that  the heart  team’s treatment recommendation 
derived from coronary CTA is in agreement with the 
recommendation derived from conventional angiography 
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Figure 4 One-year clinical outcomes among the study patients, compared with the equipoise-derived SYNTAX I PCI cohort. The Kaplan-
Meier curves show the event rate are for the SYNTAX II patients (blue) and the PCI arm of the SYNTAX I trial (red) regarding the 
composite primary (A), all-cause death/stroke/MI (B), all cause death (C); stroke (D); any myocardial infarction (E); any revascularization (F). 
Reproduced from Escaned et al. (5).
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in patients with left main or three-vessel CAD. To allow 
for the investigation of the agreement between two imaging 
diagnostic modalities on treatment recommendation 
(i.e., CABG or PCI), two heart teams were randomized 
to assess epicardial CAD either with coronary CTA or 
conventional coronary angiography in addition to clinical 
information. The heart teams comprised a cardiac surgeon, 
an interventional cardiologist and a radiologist. The 
primary end-point was agreement between two heart teams 
on treatment recommendation, i.e., agreement on one 
out of the following two options: (I) CABG only or (II) 
PCI only or equipoise between CABG and PCI, based on 
anatomical assessment of CAD. The heart team’s treatment 
recommendation relied on 4-year mortality prediction using 
the SYNTAX score II (10). 
A secondary end-point including the physiological 
component was introduced using FFR derived from 
coronary CTA (FFRCT). The SYNTAX score II, was 
re-calculated with the functional SYNTAX score and 
heart teams made a second treatment recommendation 
accounting for the flow limiting aspect of epicardial 
stenosis. Anatomical score was corrected for physiological 
significance and score points attributed to anatomical 
lesions are deducted whenever the stenotic lesion was 
not functionally significant (Anatomical score MINUS 
points for lesion not functionally significant EQUALS 
Functional SYNTAX score). The combination of the 
functional SYNTAX score with clinical characteristics 
and comorbidities is designated as the SYNTAX score III 
(Figure 6). 
The SYNTAX III Revolution trial showed that coronary 
CTA evaluation with FFRCT was feasible in patients with 
multivessel disease in 196 out of 223 patients (87.9%). 
Although the correlation between the anatomical SYNTAX 
score derived from cineangiography and multi-slice CT 
scan was moderate (Pearson coefficient of 0.59, P<0.001—
systematic error of 3.6), the SYNTAX score II derived from 
these imaging modalities had a high degree of correlation 
(Pearson coefficient of 0.99, P<0.001—systematic error 
of 0.49). The reason for that correlation increase when 
calculating the SYNTAX score II may lie in the fact that, 
for CABG, the ‘weight’ of the anatomical SYNTAX score is 
null, thus not impacting the surgical risk.
Agreement between heart teams for recommended 
treatment using either CTA or conventional angiography 
was “almost perfect” Moreover, the agreement between 
Heart Teams on the epicardial coronary vessel to be 
revascularized reached 81%. 
The inclusion of FFRCT changed the treatment decision 
in 7% of the cases and modified treatment planning in 16% 
of the cases. The results of the SYNTAX III Revolution 
trial showed that treatment decision making between CABG 
and PCI based on coronary CTA is in in almost perfect 
agreement with the decision derived from conventional 
coronary angiography in patients with left main or 3VD, 
supporting the potential role of non-invasive imaging with 
coronary CTA for treatment decision making and planning 
(Figure 7).
Image acquisition
CCTA imaging was obtained using the new generation 
CT scanner, ‘Revolution CT’ (GE Healthcare, Milwaukee, 
USA). The GE Revolution scanner has 160 mm coverage 
in the z-axis and 0.28-second rotation speed, allowing 
for acquisition of the whole heart within a single beat (28). 
Motion artefacts, if present, were corrected by post-
processing algorithm (28). Acquisitions were performed 
after administration of nitrates. Beta-blockers were 
recommended for heart rates >65 beats/min. The FFRCT 
analyses were provided by HeartFlow Inc. (Redwood City, 
CA, USA).
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Figure 5 Two-year clinical outcomes among the study patients, 
compared with the equipoise-derived SYNTAX I CABG cohort—
exploratory analysis. Kaplan-Meier curves are shown for the 
SYNTAX II group (blue) and the surgical revascularization arm 
of the original SYNTAX I trial (red) for the major adverse cardiac 
or cerebrovascular events (MACCE). Presentation of SYNTAX II 
2-year results at EuroPCR 2018, Paris, France. 
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Figure 6 Evolution of the risk score algorithms derived from the historical SYNTAX I trial. ACEF, age, creatinine, ejection fraction; 
CABG, coronary artery bypass grafting; Compos, compositional; CrCl, creatinine clearance; CSS, Clinical SYNTAX score; FSS, Functional 
SYNTAX score; GRC, Global Risk Classification; MI, myocardial infarction; MDRD, Modification of Diet in Renal Disease; SrCr, serum 
creatinine; SYNTAX, Synergy between PCI with Taxus and Cardiac Surgery.
Figure 7 Case example of assessment of CAD using the coronary computed tomography with FFRCT for functional assessment. In this case 
there is no lesion in the right coronary artery, left descending coronary artery nor circumflex. However, a severe lesion can be seen in the 
distal left main stem (yellow arrows). In the lower panel a representation of FFRCT assessment is shown. From the left main stem to both 
the LAD and LCX there is a drop in FFR (reaching 0.51 and 0.55, respectively). For this patient, the functional assessment agreed with the 
anatomical assessment. The Heart Teams decision were for CABG, based on the non-invasive assessment. CAD, coronary artery disease; 
CABG, coronary artery bypass grafting; LAD, left anterior descending; LCX, left circumflex; LM, left main; RCA, right coronary artery.
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With this technology, a nominal spatial resolution of 230 µm 
could be achieved providing information on the severity and 
extent of CAD comparable to conventional angiography (28). 
Moreover, emerging technology such as FFRCT added 
physiological information in all major coronary vessels (29). 
Epicardial coronary stenoses with lesion-specific FFRCT 
≤0.80 were considered hemodynamically significant. 
Coronary CTA were processed using three-dimensional 
maximal intensity projection images (MIP), multi-planar 
reconstructions and axial images. The anatomical SYNTAX 
score and SYNTAX score II were calculated in an 
independent core laboratory (Cardialysis BV, Rotterdam, 
The Netherlands) (10,23).
Feasibility of planning CABG relying only on coronary 
CTA
For the surgical community, the feasibility to perform 
CABG based solely on coronary CTA and FFRCT would 
depend primarily on the precise recognition of a landing 
zone for the anastomosis of the graft in the coronary 
artery. Therefore, the non-invasive assessment of the 
entire coronary artery is crucial for planning CABG. The 
distal segment is important for assessing landing zones, 
while evaluation of the proximal artery segments does not 
impact on anatomical planning but plays a major role in the 
functional assessment of stenosis. Also, the surgeon’s pre-
operative assessment of the feasibility of grafting the artery 
depends mainly on the quality and size of the target vessels, 
i.e., diameter and calcification pattern may be useful for 
surgical planning.
The most challenging scenario for coronary CTA is 
the presence of calcified plaques that (due to the blooming 
artefact) hamper luminal evaluation (30). Calcified stenosis 
located in the proximal segment of the coronary arteries 
does not pose a problem for surgeons because the 
anastomoses are performed at the distal segments of the 
coronary arteries. Furthermore, in several cases included 
in the trial, the presence of calcification at the level the 
aortic root warned the surgical team that manipulation 
at this level or cross-clamping might be associated with 
a higher risk of stroke, leading them to adapt a surgical 
technique aimed at reducing periprocedural complications 
(31-33) (Figure 8).
Implication of the SYNTAX III Revolution study for 
the surgical community
In patients with multivessel disease, the guidelines 
recommend a multidisciplinary heart team discussion, 
taking into consideration the anatomical complexity of 
the CAD, as well as the patient’s clinical characteristics 
and comorbidities (1,22). For decades, the gatekeeper 
for surgical revascularization has been the cardiologist 
performing diagnostic coronary angiography. In patients 
with low anatomical complexity, assessed by an anatomical 
SYNTAX score ≤22, PCI can be considered as an 
alternative to CABG (1,22). In patients with anatomical 
SYNTAX score >22, CABG provides superior clinical 
outcomes compared to PCI (2). SYNTAX III Revolution 
incorporates the radiologist into the heart team discussion, 
potentially shifting the gatekeeping process to the 
radiologist and allowing for treatment decisions and 
planning based solely on non-invasive imaging. This may 
potentially impact surgical practice, integrating non-invasive 
imaging and heart team’s discussion before the patient goes 
to the catheterization laboratory or the operative room.
Surgical revascularization planning is customarily based 
on the anatomical severity of coronary stenosis. Recently, 
several trials have demonstrated the benefit of guiding 
revascularization based on the physiological repercussions of 
anatomical stenosis. FFR-guided CABG is associated with 
a significant reduction in the rate of overall death or MI 
Figure 8 3D-maximum intensity projection (MIP). Coronary 
computed tomography CT reconstruction of the aortic root 
and coronary arteries showing intense calcification in the left 
descending coronary artery and also in the aortic root. This image 
warns the surgeon for adapting coronary artery bypass surgical 
technique due to the intense calcification of the aorta.
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at 6-year follow-up as compared with angiography-guided 
CABG (17). Nonetheless, systematic three-vessel pressure 
wire evaluation to determine FFR or other resting index is 
time consuming and seldom performed in clinical practice. 
The assessment of FFRCT before surgical revascularization 
has the potential to increase physiology-guided CABG, 
potentially improving clinical outcomes after surgical 
revascularization.
Conclusions
The SYNTAX III Revolution trial was a decision-
making study and the decision of the heart teams were 
not bound to the revascularization strategy performed. 
It was demonstrated that treatment decisions were the 
same, regardless of whether coronary CTA or coronary 
angiography were used for evaluation by the heart team, 
however, whether this same equipoise would occur between 
imaging modalities in the real-world setting remains to be 
confirmed. A clinical outcome randomized trial comparing 
a coronary CTA with FFRCT strategy versus standard of 
care is required in order to introduce this strategy in routine 
clinical practice. 
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